Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up.
about
Neurology of the vasculitides and connective tissue diseasesPlasma viscosity in giant cell arteritis as a predictor of disease activity.The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment.Interleukin-6 in clinical relapses of polymyalgia rheumatica and giant cell arteritis.A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis.Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Groupe de Recherche sur l'Artérite à Cellules Géantes.EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT).A disease activity score for polymyalgia rheumatica.Best practice in primary care pathology: review 2Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis.Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study.Progress in gerontology: polymyalgia rheumatica and temporal arteritis.Predictive clinical and laboratory factors in the diagnosis of temporal arteritis.Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis.Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica.PG2 for patients with acute spontaneous intracerebral hemorrhage: a double-blind, randomized, placebo-controlled study.Recent advances in diagnostic strategies for giant cell arteritis.Systematic review of the literature and a case report informing biopsy-proven giant cell arteritis (GCA) with normal C-reactive protein.Clinical features of polymyalgia rheumatica and giant cell arteritis.Polymyalgia rheumatica: 125 years of progress?Polymyalgia rheumatica: 125 years of epidemiological progress?Epitope mapping of antibodies against ferritin heavy chain in giant cell arteritis and polymyalgia rheumatica.Treatment of polymyalgia rheumatica and giant cell arteritis.Recognition of giant cell arteritis in patients with polymyalgia rheumatica who have a stroke: a cautionary tale.Giant cell arteritis: A rare cause of posterior vasculitis.Giant cell arteritis presenting as a periorbital pain syndrome and a submandibular mass.Assessment of 2012 EULAR/ACR new classification criteria for polymyalgia rheumatica in Japanese patients diagnosed using Bird's criteria.
P2860
Q24679901-EC682C18-1BB7-4996-BC82-EC31DBE7BAFDQ33565279-2B32C0CB-3439-406E-B750-AD4DCF662589Q33565959-C7380B69-5279-4065-8554-CC9E07041F89Q33579015-0361804E-2601-4102-AE18-00C0B6B02186Q34587431-A6533A39-70C5-47DD-A4E2-9A5C492F8C8EQ35548661-D8AE1E09-4A8B-48BC-AEB0-C7803609F036Q35552286-BD678E50-41BF-48AB-AFB2-E2B9496E04CCQ35553332-8BAB98F8-DD98-4438-84F4-E3F96CC169C2Q35769740-28A906F1-B578-4517-9892-5C8444EDD88DQ35840268-8BA356EB-5FD2-4A76-868D-A05E2ABCF8C6Q35861674-F671C1AA-628F-457A-A336-9709E52F630EQ36339982-5FF17932-8186-4045-9AB8-6881390CD751Q36823038-20E40E8E-A7E6-47A9-8DFF-1F64ABBF8BD0Q36843077-E811E894-CC9A-4EC4-8CF8-B79C9F3221A3Q36963349-0278D4ED-AAD9-4E81-86F3-03C79E4554DDQ37498527-D11083F6-E9F8-49FA-BEF8-3F8BFDA6FAB0Q37731512-08A46B66-BE06-4755-8CA9-088D8830124EQ37972084-D9D6AB53-7E69-466C-9FC4-F36F78822885Q38028355-7398872B-F55A-415C-8851-659B8E6913CAQ38028863-7E5699EC-F851-401E-8CD2-A6B18772F262Q38247259-B43D916E-AD8B-4268-B421-15845ED63275Q38247260-F096C161-F571-4975-A129-46710FDD6247Q40247458-2C90D0A3-9291-428E-A365-08242D0B2919Q41225354-4AB69562-249A-43DB-829E-91EFDB935EACQ41989277-866DF890-96ED-4042-8A80-777C7C7B9358Q43096337-940DBE13-7BB6-47CB-A2D2-B21C7985B35AQ44418458-85A38553-8202-4E50-8DB6-956B0A25007FQ51109445-1174C9E5-5D8B-4C04-B31F-B225FA3A6B3E
P2860
Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up.
description
1989 nî lūn-bûn
@nan
1989 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Erythrocyte sedimentation rate ...... entation and during follow up.
@ast
Erythrocyte sedimentation rate ...... entation and during follow up.
@en
Erythrocyte sedimentation rate ...... entation and during follow up.
@nl
type
label
Erythrocyte sedimentation rate ...... entation and during follow up.
@ast
Erythrocyte sedimentation rate ...... entation and during follow up.
@en
Erythrocyte sedimentation rate ...... entation and during follow up.
@nl
prefLabel
Erythrocyte sedimentation rate ...... entation and during follow up.
@ast
Erythrocyte sedimentation rate ...... entation and during follow up.
@en
Erythrocyte sedimentation rate ...... entation and during follow up.
@nl
P2093
P2860
P356
P1476
Erythrocyte sedimentation rate ...... entation and during follow up.
@en
P2093
P2860
P304
P356
10.1136/ARD.48.8.667
P407
P577
1989-08-01T00:00:00Z